34,850 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Acquired by DCF Advisers LLC

Key Points

• DCF Advisers LLC has acquired a new stake in AnaptysBio, purchasing 34,850 shares valued at approximately $648,000 in the first quarter.
• Several institutional investors, including HighMark Wealth Management and Vanguard Group, have also made significant investments in AnaptysBio, indicating a growing interest in the company.
• Analysts have raised their price targets for AnaptysBio, with JPMorgan Chase increasing its target from $42.00 to $80.00, reflecting strong confidence in the company’s future performance.

DCF Advisers LLC bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 34,850 shares of the biotechnology company's stock, valued at approximately $648,000. DCF Advisers LLC owned approximately 0.12% of AnaptysBio at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its holdings in shares of AnaptysBio by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company's stock valued at $880,000 after purchasing an additional 528 shares in the last quarter. Rhumbline Advisers increased its position in AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock worth $574,000 after buying an additional 826 shares during the last quarter. Virtus ETF Advisers LLC grew its position in shares of AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 936 shares during the last quarter. US Bancorp DE grew its position in shares of AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 979 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in shares of AnaptysBio by 10.3% in the fourth quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company's stock valued at $193,000 after purchasing an additional 1,359 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ANAB. Wedbush reiterated an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research note on Thursday, May 29th. HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and upped their price target for the stock from $22.00 to $38.00 in a report on Wednesday, June 4th. Guggenheim reiterated a "buy" rating and issued a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. Finally, JPMorgan Chase & Co. boosted their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, AnaptysBio currently has an average rating of "Moderate Buy" and a consensus target price of $47.13.

AnaptysBio Trading Down 3.9%

Shares of NASDAQ:ANAB traded down $0.92 during mid-day trading on Wednesday, reaching $22.78. The company had a trading volume of 79,371 shares, compared to its average volume of 776,995. The company's 50-day moving average price is $24.23 and its 200-day moving average price is $20.37. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $41.31. The firm has a market cap of $669.13 million, a price-to-earnings ratio of -4.69 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million for the quarter, compared to analysts' expectations of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative return on equity of 282.47%. On average, research analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

Insider Activity at AnaptysBio

In other news, Director Hollings Renton sold 20,925 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the transaction, the director directly owned 4,965 shares in the company, valued at $117,025.05. The trade was a 80.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.50% of the stock is owned by company insiders.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.